' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data
Rohracher, A; Kalss, G; Leitinger, M; Granbichler, C; Deak, I; Dobesberger, J; Kuchukhidze, G; Thomschewski, A; Hofler, J; Trinka, E
THER ADV NEUROL DISO. 2016; 9(6): 445-453.
Originalarbeiten (Zeitschrift)

PMU-Autor/inn/en

Deak Ildiko
Dobesberger Judith
Höfler Julia
Kalss Gudrun
Kuchukhidze Giorgi
Leitinger Markus
Rohracher Alexandra
Thomschewski Aljoscha
Trinka Eugen

Abstract

BACKGROUND
The aim of this study was to analyse registry data of seizure outcome and adverse events (AEs) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years.
A retrospective 2-year chart review of all patients receiving perampanel was carried out.
A total of 122 patients received perampanel [median treatment length: 20.1 (range: 3.4-26.8) months]; 71 (58%) remained on treatment at last follow up. Overall, 33 patients (27%) were seizure-free for ⩾3 months at last follow up; of these, eight were seizure free for ⩾3 times the longest interictal interval before perampanel therapy; 18 (15%) had reduced seizure frequency ⩾50%. A total of 58 (47%) had an AE and 34 (28%) withdrew from treatment because of AEs. AEs included dizziness (33%), fatigue (12%), psychiatric symptoms (8%), cognitive deficits (7%), speech problems (5%), nausea (4%) and gait problems (4%). AEs subsided in 17/18 patients (94%) following a 2 mg dose reduction. A total of 43 (35%) took a concomitant enzyme inducer. Patients not taking enzyme inducers were more likely to be seizure free (p = 0.002); there were no other between-group differences.
Perampanel was well tolerated and improved seizure control in 42% of patients (50- 100% reduction), with higher rates in those not receiving a concomitant enzyme inducer. AEs, particularly dizziness, were common but often disappeared with a slight dose reduction. The results are consistent with those from randomized controlled trials.


Find related publications in this database (Keywords)

clinical experience
efficacy
focal epilepsy
perampanel
tolerability